Epitalon: Khavinson's program, telomerase and what still needs replication

What epitalon is and where it comes from

Epitalon (also epithalon or AEDG) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly. It was designed from the amino-acid composition of epithalamin, a peptide complex extracted from the bovine pineal gland, and was later identified in that same mixture¹². It originates at the St. Petersburg Institute of Bioregulation and Gerontology, Professor Vladimir Khavinson's group⁸.

This is a long research program. As early as 1982 the group reported longer life span and lower tumor incidence in C3H/Sn mice treated with polypeptide factors from the thymus and epiphysis¹. A 2025 Polish review summarizes the last 25 years of in-vitro, in-vivo and in-silico epitalon studies¹². The product page is at Epitalon; for a comparison with MOTS-c, NAD+ and SS-31, see Epitalon, MOTS-c, NAD+ and SS-31.

The telomere hypothesis, in the laboratory

The work that made epitalon famous was published in 2003. In telomerase-negative human fetal fibroblast cultures, adding the peptide was associated with expression of the enzyme's catalytic subunit, its enzymatic activity and telomere elongation².

A year later the same group used pulmonary fibroblasts from a 24-week fetus, which lost the ability to divide at passage 34. With epitalon, telomeres lengthened to a size comparable to early passages and the cells made 10 additional divisions (44 passages) and kept dividing. The authors described this as overcoming the Hayflick limit³.

Animals: aged mice and monkeys

The most cited mouse study included 54 female mice per group, treated from 3 months of age until natural death on 5 consecutive days each month. Epitalon did not change food intake, body weight or mean life span. It was associated with slower age-related loss of estrous function, 17.1% fewer chromosome aberrations in bone marrow, a 13.3% increase in the life span of the last 10% of survivors and a 12.3% increase in maximum life span. Total spontaneous tumor incidence did not change, but leukemia was 6.0-fold less frequent. The authors concluded that the data suggest geroprotective activity and safety of long-term administration in mice⁴.

In rhesus monkeys aged 20 to 27 years, epitalon was associated with lower basal glucose and insulin, higher nocturnal melatonin and a better response to a glucose load. It had no effect in young animals⁵. That pattern, acting on what is disturbed and not on what is normal, reappears in the human melatonin study⁶.

Humans: melatonin, retina and mortality

In healthy older adults, a course of epithalamin was associated with higher nocturnal melatonin in those with reduced pineal function, while in those with normal function the concentration tended to fall⁶. The authors interpret this as modulation, not simple stimulation.

The mortality data are the most striking. In a 12-year randomized study of older adults with coronary disease and accelerated cardiovascular aging, the epithalamin group had 28% fewer deaths and half the cardiovascular mortality of the control group⁷. In another cohort of 266 older people followed for 6 to 8 years, mortality was 1.6 to 1.8 times lower with epithalamin⁸. It is worth stressing: these data are for epithalamin, the extract, not synthetic epitalon.

For epitalon itself, the FDA found three human studies: two with sublingual administration in night-shift workers and one with parabulbar injection in retinitis pigmentosa¹³. In the latter, Khavinson's group reported a positive clinical effect in 90% of cases⁹. Epitalon received an orphan drug designation for retinitis pigmentosa in 2010, withdrawn in 2016¹³.

What independent research has added

In 2025 a team at Brunel University London, with no declared conflicts of interest, treated normal epithelial cells and fibroblasts and two breast cancer lines (21NT and BT474). In normal cells it observed dose-dependent telomere elongation through upregulation of hTERT mRNA and telomerase activity. In the tumor lines, elongation occurred through a different route, the ALT mechanism (alternative lengthening of telomeres)¹⁰.

The same year, an Italian group working with St. Petersburg found that, in retinal pigment epithelial cells injured by high glucose, epitalon restored in-vitro wound healing and inhibited epithelial-mesenchymal transition and fibrosis¹¹. The Warsaw review adds that, despite the volume of biological data, it remains unclear whether telomerase and melatonin are its only mechanisms, and that physicochemical and structural studies are scarce¹².

Where the evidence ends

The first limit is one of origin, and it does not diminish the work. Of the nine references in this article published before 2025, all have Khavinson or Anisimov as an author^123456789, and several appeared in Russian journals or their translations. Independent replication is only beginning¹⁰.

The second is regulatory. In its 2026 briefing document the FDA found no pharmacokinetic data and wrote that it "has not identified clinical studies assessing the safety of epitalon-related BDSs administered in humans". Its adverse-event database search through December 8, 2025 retrieved no reports. On mechanistic grounds, the agency noted that epitalon "has the potential to be carcinogenic", and that the mouse studies, with a fixed dose, females only and short exposure, are not enough to rule this out¹³. The ALT finding in tumor cells is consistent with that caution¹⁰.

Even so, the advisory committee voted 7–5, with one abstention, to add epitalon to the compounding list for insomnia, overriding FDA staff¹⁴. The details are in What the FDA really said about peptides.